TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time of onset of Vincristine Induced Peripheral Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of Vincristine Induced Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Vincristine Induced Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Time until neonate is awake after sedation interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until neonate is extubated after sedation interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ctDNA Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMC278LA concentrations in the genital tract and rectal compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wall Shear Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection Rates for Adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection Rates for Total Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dental restoration assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Function Non-deterioration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Experience an Adverse Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in performance of GMLT and MDR tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reliable detection of epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation between laboratory and point-of-care clotting tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of episodes of abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of episodes of fecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of defecation consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pain in the affected knee joint (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in pain in the affected knee joint (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lipid/lipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % responders to antipsychotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR)-15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical healing of the skin injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Circulating or excreted biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apathy Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Flow Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of T-score of total score of child behavior checklist 1.5-5 (CBCL 1.5-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of T-score of each internalizing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of T-score of each externalizing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported screening and counseling by physicians
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Esophageal Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Full Donor Chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Toxicity for the Combination of Pentostatin and Low Dose Total Body Irradiation (TBI)
Endpoint domain: Adverse events/effects
Primary endpoint: inflammation (IL-6 concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: oxidative stress (CAT concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes self-care attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of Related Adverse Events - Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Self-assessed Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: conversion rate of latent tuberculosis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of early metastases in lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Analgesia assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurodevelopment changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: neurodevelopment changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neurodevelopment changes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Intentions to be Screened for Colorectal Cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postpartum blood loss equal to or greater than 500 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Odds of developing lung cancer according to biomarker status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of taste disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of the four basic flavors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial disease progression free survival time
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Reporting One or More Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 2 or Higher Laboratory Test Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Endocrine variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Irisin level assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle mass assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle quality assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants who have One or More Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants who have One or More Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Head mark or injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Implant-Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Facial electromyographic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory markers in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in inflammatory markers in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in immune markers in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in immune markers in muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in blood pressure and pulse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anthropometric evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of Recurrence Through Week 8
Endpoint domain: Mortality/survival
Primary endpoint: WOMAC Pain sub-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squelch effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Misophonia Total Score (MTS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: area under the plasma concentration curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of bicalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PAC classification modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of practitioners using selected methods for caries diagnosis and treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Forced Expiratory Volume in One Second (FEV1) %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bone metabolism markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Hemoglobin Level at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiographic Densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-baseline Newly Occurring or Worsening PCS Clinical Chemistry Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-baseline Newly Occurring or Worsening PCS Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-baseline Newly Occurring or Worsening PCS ECG Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in speech perception accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MTD of Erlotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of Bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of Subjects With Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Primary molecular diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fMRI brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-operative Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in dry eye symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cohen's Kappa Coefficient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Percentage of Children Meeting Physical Activity Policy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Attention capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of collected stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) at 1 minute post-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plantar foot pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bloodflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular reserve index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EMG Muscular Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frown Wrinkle Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence comparison of anti-PSMA marked prostate biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Overall Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With HIV-ribonucleic Acid (RNA) >=50 Copies Per Milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low back and leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood pressure (systolic/diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in family coping behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Localization of adrenal tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of adrenal tumor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BOLD signal in the orbitofrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Treatment Success at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Composite List of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 1 Repetition maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bicep Muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bicep muscle endurance testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Last Quantifiable Plasma Concentration (Clast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma-Concentration Curve from Time 0 to Infinite Time (AUCinfinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Blood Pressure measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained virologic response (SVR) 12 weeks after discontinuation of study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf] of Galcanezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle gene expression modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal oxygen uptake (CPX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GH deficiency or GH resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ispinesib
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement of complete or partial remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in painful days per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent Change in Worst Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 1st audible intestinal sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Asthma Control Test Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the concentration-time curve of the analyte in the plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analyte in the plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of PET MR in Multiple Myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants That Responded to Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography (EMG) of the Orbicularis oculi muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Acetylcholine-stimulated nitric oxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of clinically significant changes in laboratory parameters, 12 lead ECG parameters, vital signs measurements, spirometry, and physical examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Oxidative stress index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total droplet area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single muscle fiber cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single muscle fiber maximal force (Po)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative occurrence of VTE events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Cardioversion of Atrial Fibrillation to Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose of monoclonal antibody ch14.18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of arterial cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of PE diagnosis with CTPA imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical Cure: Respiratory rate below age specific cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to develop clinical deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Distribution Expressed Relative to Total Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Length Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence and treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events (AEs) leading to treatment discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Nutritional status (Z-score or BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival at 30 Days After Last Dose of Tigecycline
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Device and Procedure Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Treated With Technical Success of the Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Device Performance Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC of edasalonexent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-first symptomatic AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum volitional EMG in the extensor digitorum and the finger flexors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Repetitive behavior scale revised (RBS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress Levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Relapse (Quantile 25%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardised Mean Change in Age-adjusted IGF-1 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes